时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Which checkpoint is blocked, and whether one or two are blocked, therefore sets a baseline level and organ distribution of risk before any individual characteristic is considered.
方法
The strongest single-variant evidence comes from a genome-wide association study of 1,751 patients treated with ICIs across 12 cancer types, which identified a common variant near IL7 (rs16906115) associated with all-grade irAEs, with a hazard ratio of roughly 2.1 and replication in independent cohorts ().；Critically, in a melanoma cohort the same risk allele that increased severe irAE risk independently associated with improved survival (), the review’s recurring duality in its cleanest form: a single inherited variant that raises both toxicity and benefit.；The clearest demonstration comes from a melanoma cohort genotyped at HLA-DR, in which distinct DR alleles were each associated with a distinct tissue-specific irAE, confirming earlier single-toxicity reports of DR4 with type 1 diabetes, DR15 with hypophysitis and DR11 with pneumonitis ().
核心结论
By releasing the inhibitory signals that normally restrain T-cell activation, ICIs can break self-tolerance and provoke immune-related adverse events (irAEs) that affect virtually any organ system, ranging from transient and low-grade to chronic, disabling, or fatal (; ).；The intensity and pattern of toxicity scale with the regimen: combination CTLA-4 and PD-1 blockade produces grade 3 or 4 treatment-related events in roughly 55% of patients, compared with about 16% for PD-1 monotherapy, a more than threefold difference driven by the drugs rather than the patient ().；Toxicity also carries a class signature, with anti-CTLA-4 agents disproportionately associated with colitis and hypophysitis and anti-PD-1 agents skewing toward pneumonitis, thyroid dysfunction, and vitiligo (). ‖ 结论：Collectively, the reviewed evidence demonstrates that the risk of irAEs is unevenly distributed among patients in ways that cannot be explained solely by the treatment regimen.
局限
As a narrative synthesis, this review carries limitations that bear on how its conclusions should be read.
对本项目的价值
★☆☆☆☆ 炎症衰老是几乎所有慢性老年病的公共通路，也是最有希望做「抗炎但保留免疫」解耦的靶点。
全文来源
PMC JATS 全文（正文 40,226 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Host determinants of immune-related adverse events during immune checkpoint inhibition.
- 期刊与标识：Front Pharmacol · PMID 42953392 · DOI 10.3389/fphar.2026.1941544
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。